Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon [Seeking Alpha]
Corvus Pharmaceuticals, Inc. (CRVS)
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corvuspharma.com
Company Research
Source: Seeking Alpha
75% of patients on 200 mg soquelitinib BID achieved EASI 75, with benefits persisting one month post-treatment. Longer treatment duration improved outcomes, including for patients previously treated with other therapies. Soquelitinib's value extends beyond AD, with ongoing phase 3 PTCL and phase 2 studies supporting further upside. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Thicha Satapitanon/iStock via Getty Images The last time I spoke about Corvus Pharmaceuticals, Inc. ( CRVS ), it was in a Seeking Alpha article entitled " Corvus Pharmaceuticals: Positive Phase 1 Soquelitinib Trial Data Brings 2025 Catalysts. " With respect More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe, I'm currently offe
Show less
Read more
Impact Snapshot
Event Time:
CRVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVS alerts
High impacting Corvus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRVS
News
- Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $30.00 price target on by analysts at Mizuho.MarketBeat
- Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study [Yahoo! Finance]Yahoo! Finance
- Why Corvus Pharmaceuticals (CRVS) Is Up 211.8% After Upsized Equity Raise On Soquelitinib Phase 2 Plans [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201MGlobeNewswire
CRVS
Earnings
- 11/4/25 - Beat
CRVS
Sec Filings
- 2/5/26 - Form SCHEDULE
- 1/30/26 - Form 4
- 1/30/26 - Form SCHEDULE
- CRVS's page on the SEC website